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Abstract Tumors of the heart and the great vessels are
very rare disease, and there are many disorders such as
tumors originated from the heart and great vessels, meta-
static tumors, and tumor-like lesions which do not fit into
the usual concept of tumor or neoplasm; thus, it is very
difficult to classify these tumors. We proposed a new
classification of cardiovascular tumors for clinical use
based on the accumulated biological analyses and clinical
data of the reported literatures and our own study as benign
tumors, malignant tumors, ectopic hyperplasia/ectopic
tumors/others, and tumors of great vessels, with reference
to the series of Atlas of tumor pathology of the Armed
Forces Institute of Pathology and the recent World Health
Organization classification of cardiac tumors issued in
2004. More than 50 disorders have been reported as tumors
originated from the cardiovascular system, and various
metastatic tumors from nearby organs, distant lesions, and
intravascular extension tumors to the heart were reported.
Based on the new classification, we reviewed epidemiology
and incidence of cardiovascular tumors. Metastatic tumors
are more frequent than tumors originated from the heart
and great vessels, and cardiac myxoma is the most frequent
tumors in all cardiac tumors.
Keywords Cardiac tumor  Metastatic cardiac tumors 
Classification  Incidence  Cardiac myxoma
Introduction
Tumors of the cardiovascular system, benign or malignant,
are very rare disease, and there are many disorders which
do not fit into the concept of tumor or neoplasm; thus, it is
very difficult to classify the tumors of the heart and great
vessels. As tumors of other organ, tumor of the heart and
great vessels are classified as tumors originated from the
heart and great vessels, or secondary/metastatic tumor with
invasion nearby organs such as lung or metastatic tumors
that occur in the distant organ. In addition, tumors origi-
nated from the heart are classified by the site of tumor
location such as tumor of the heart, cardiac septum, peri-
cardium, or great vessels, and classified by cell type con-
stituting the tumor such as hyperplasia, hamartoma, cyst, or
benign or malignant, and also classified by histological
features such as mesenchymal, epithelial, and serous
membrane (mesothelium). However, there is no established
standard method of classification of tumors of the heart and
great vessels up to now. In this review, we propose a new
clinical classification for tumors of the cardiovascular
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system, and summarize its epidemiology and incidence
from the reported literatures and our own study.
Classification of tumors of the heart and great vessels
Tumors originated from the heart and great vessels are
found at an incidence of about 0.02 % of autopsy. Among
these cardiovascular tumors, 70 % of these tumors and
most of the surgically excised tumors are benign [1]. Since
there is no counterpart tumor in other organs or lack of
histogenetical and pathological evidence of true tumor for
papillary fibroelastoma, histiocytoid cardiomyopathy,
lipomatous hypertrophy of the interatrial septum or cystic
tumor of atrioventricular node, and others, pathological
classification is very difficult for these tumors [2]. And
also, it seems difficult to classify the tumors by histological
type, because there are many tumors whose origin is not
clear like tumors appear in other organs and tissues. A
typical example is that in cardiac myxoma, origin of car-
diac myxoma and tumor characteristics is not yet eluci-
dated, and it contains various cell components like
epithelium, endothelium, nerve, and undifferentiated
mesenchyma which potentially differentiate into many
tissues such as blood vessels, glandular structures, bones,
and foci of extramedullary hematopoiesis [3]. Also, sar-
coma is a malignant cardiovascular tumor, and despite very
low incidence, many types of sarcomas which found in
other organs were reported in the literatures [4]. However,
there is so-called undifferentiated sarcoma exists that
cannot determine a certain tendency to differentiate into
cells or tissues even if using the latest diagnostic technol-
ogy such as immunohistochemistry, electron microscopy
and genetic analysis [5].
Because there are many cardiac tumors whose origin is
not yet determined and cell differentiation was not eluci-
dated, it is very difficult to systematically classify these
tumors. According to the well-known classification of
‘‘tumors of the heart and great vessels’’ (Armed Forces
Institute of Pathology: AFIP) published in 1996 [3]
(Table 1), cardiac tumors including both cardiac tumors
and pericardial tumors are classified into benign or
malignant cardiac tumors. Sarcomas of the aorta and pul-
monary artery, sarcomas of the inferior vena cava, and
leiomyomatosis of veins are classified in different catego-
ries. Benign cardiac tumors are further classified as tumors
of unknown histogenesis, tumors of cardiac muscle, tumor
of fibrous tissue, vascular tumors and tumor-like lesions,
tumors and proliferations of fat, tumors and tumor-like
lesions of mesothelial cells, tumors of neural tissue, tumors
of smooth muscle, heterotopias, and tumors of ectopic
tissue. And malignant cardiac tumors are classified as
sarcomas, malignant germ cell tumors, hematologic
Table 1 Classification of ‘‘tumors of the heart and great vessels’’ by
the Armed Forces Institute of Pathology
Benign cardiac tumors
Tumors of unknown histogenesis
Myxoma
Papillary fibroelastoma
Tumors of cardiac muscle
Rhabdomyoma
Histiocytoid cardiomyopathy (purkinje cell hamartoma)
Miscellaneous hamartomas
Tumors of fibrous tissue
Fibroma
Solitary fibrous tumor of pericardium
Benign fibrous histiocytoma
Inflammatory pseudotumor






Tumors and proliferations of fat
Lipomatous hypertrophy, interatrial septum
Lipomatous hamartomas of cardiac valves
Lipoma
The fatty heart
Tumors and tumor-like lesions of mesothelial cells
Mesothelial cysts
Mesothelial/monocytic incidental cardiac excrescences
Mesothelial papilloma




Tumors of smooth muscle
Leiomyoma
Intravascular leiomyomatosis
Heterotopias and tumors of ectopic tissue
Bronchogenic/foregut cysts
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tumors, granulocytic sarcoma, mesothelial malignancies,
and metastatic tumors to the heart.
The recent classification by WHO in 2004, tumor of the
heart are divided into three categories: benign tumors and
tumor-like lesions, malignant tumors, and pericardial
tumors [4] (Table 2). In benign tumors, tumor were clas-
sified as tumor showing differentiation into muscle cells
such as rhabdomyoma, adult cellular rhabdomyoma, ham-
artoma of mature cardiac myocytes, and histiocytoid car-
diomyopathy. Cardiac myxoma and papillary fibroelastoma
are classified as pluripotent mesenchymal origin, and car-
diac fibroma and inflammatory myofibroblastic tumor were
classified as tumor showing differentiation into myofib-
roblastic cell. Other benign tumors are vascular tissue
origin as hemangioma, fat tissue origin as lipoma, and
congenital cystic lesions in the atrioventricular node as
cystic tumor of atrioventricular node. This classification
includes relatively high incidence of benign cardiac
tumors, however, tumors of low incidence such as tumors
of neural cell differentiation or smooth muscle cell dif-
ferentiation are not included. Most prominent differences
of WHO classification from AFIP classification are clas-
sification of malignant tumors. Firstly, epithelioid heman-
gioendothelioma, formerly classified as benign tumor has
been classified as malignant tumor, and secondarily
undifferentiated sarcoma, which has been classified as
tumor of unknown origin, is united to form one disease as
malignant pleomorphic fibrous histiocytoma (MFH)/
undifferentiated pleomorphic sarcoma subtype. Other
Table 2 WHO histological classification of tumors of the heart
Benign tumors and tumor-like lesions
Tumors of muscle cell differentiation
1. Rhabdomyoma
2. Histiocytoid cardiomyopathy/purkinje cell hamartoma
3. Hamartoma of mature cardiac myocytes





Tumors myofibroblastic cell differentiation
1. Cardiac fibroma
2. Inflammatory myofibroblastic tumor/Inflammatory
pseudotumor
Cardiac lipoma





3. Malignant pleomorphic fibrous histiocytoma (MFH)/
undifferentiated pleomorphic sarcoma






Metastatic tumors to the heart
Pericardial tumors
1. Solitary fibrous tumor
2. Malignant mesothelioma
3. Germ cell tumors
4. Metastatic pericardial tumors
Modified from reference [4]
















Metastatic tumors to the heart












Malignant fibrous histiocytoma (MFH)
Unclassified sarcomas




Modified from reference [3]
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features of WHO classification are malignant mesenchy-
moma, osteosarcoma, chondrosarcoma, and many other
sarcomas were not included as an independent sarcoma, but
included in MFH/undifferentiated pleomorphic sarcoma,
and tumor that had been referred to as myxosarcoma spe-
cific for heart was classified as a subtype of myxoid
fibrosarcoma.
Since the AFIP classification of the heart, pericardium,
and great vessels has been widely used, we propose a new
classification based on AFIP classification, with reference
to the WHO classification and taking into account the
recent findings of cell differentiations and clinical impor-
tance [6] (Table 3). Cardiac tumors are classified as benign
tumors, malignant tumors, and ectopic cardiac tumors and
other tumors. Benign tumors are classified into cardiac
tumors and pericardial tumors. Malignant tumors are
classified as tumors originated from the heart, metastatic
cardiac tumors, intravascular tumors with extension to the
heart, and malignant pericardial tumors. The tumors of
ectopic cardiac tumors and other tumors are tumors of
unknown origin, ectopic other tissue formation within the
Table 3 Classification of tumors of the heart and great vessels: new






Tumors and tumor-like lesions of muscle cell differentiation
3. Rhabdomyoma
4. Leiomyoma
5. Histiocytoid cardiomyopathy/purkinje cell hamartoma
Tumors of fibroblast and myofibroblast cell differentiation
6. Cardiac fibroma
7. Inflammatory myofibroblastic tumor/inflammatory
pseudotumor





Tumors and tumor-like lesions of adipocyte differentiation
12. Lipomatous hypertrophy
13. Lipoma
14. Lipomatous hamartoma of cardiac valves
Tumors of nerve cell and nerve sheath differentiation




Other cardiac tumors and tumor-like lesions
19. Teratoma
20. Hamartoma
21. Cystic tumor of atrioventricular node
II. Pericardial tumors and tumor-like pericardial lesions
22. Solitary fibrous tumor of the pericardium
Table 3 continued
23. Mesothelial papilloma
24. Intrapericardial thymoma/pericardial thymoma
25. Pericardial cyst
Malignant tumors
I. Cardiac tumors originated from the heart
1. Angiosarcoma
2. Cardiac intimal sarcoma
3. Epithelioid hemangioendothelioma










II. Metastatic cardiac tumors
1. Direct invasion
2. Metastasis
III. Intravascular extension tumors
1. Renal cell carcinoma




3. Leukemic infiltration of the pericardium
Ectopic hyperplasia/Ectopic tumors  Others
1. Aberrant goiter/Thyroid heterotopia/ectopic thyroid
2. Bronchogenic cyst
3. Mesothelial/Monocyte incidental cardiac excrescence (MICE)
4. Blood cyst
5. IgG4-related sclerosing disease
6. Immunodeficiency-associated lymphoproliferative disorder
7. Wegener’s granulomatosis
8. Calcified amorphous tumor
9. Thrombus
Tumors of the great vessels
1. Aortic tumors
2. Pulmonary artery tumors
3. Tumors of the great veins
Modified from reference [6]
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heart, tumor-like lesions due to immunological or hema-
tological disorders, and apparently no tumor lesion but
should be differential diagnosed. IgG4-related sclerosing
disease are included in this classification as a cardiac
tumor, since this disorder are reported to be systemic
immunological disorder and forming lesions in the salivary
glands as well as pancreas and tumor-like lesion in the
heart. In addition, the immunodeficiency-associated lym-
phoproliferative disorder due to the recent spread of AIDS
has been included in this category. Thrombus is not a true
tumor, and it was not included in the AFIP classification.
We picked up thrombus as ‘‘other disease’’, because it is
useful for routine clinical differential diagnosis when
intracavitary or intravascular lesions is encountered.
Tumors of the great vessels are further rare tumors
compared to the cardiac tumors. Most of them have been
malignancies in the aorta, pulmonary artery, and vena cava,
and the high incidence in the venous system. The classi-
fication of the tumors of great vessels is not well estab-
lished because of its very low incidence and lack of
pathological analyses [7]. For malignant tumor that occurs
in the aorta, Iwabuchi [8] classified aortic tumors following
two types, i.e., intimal or luminal type which main lesion is
in the intima, and the mural type which main lesion is in
the media to adventitia, since histological classification did
not reflect patient prognosis, but tumor locations and shape
is clinically important. In particular, the intimal type of
tumor when tumor is protruding and exposed to the vessel
lumen resulting strong degeneration and necrosis, is diag-
nosed as intimal sarcoma, because it may be difficult to
diagnose pathology correctly due to poor pathological
specimen.
Our new classification of tumors of the heart and great
vessels are based on the ‘‘tumors of the heart and great
vessels’’ AFIP [1] and the WHO classification [4]. The
pathological and clinical entities of these tumors were not
well established compared with other organs such as
tumors of the digestive system, and the WHO classification
classified only typical tumor and major cardiac tumors and
tumor-like lesions. In our classification, we intended to
include almost all the tumors and tumor-like lesions of the
heart and great vessels for clinical use based on the idea of
the authors. Since this classification is not perfect and did
not based on fully pathological aspects, we sincerely hope
that the more precise and useful classifications will be
established in accordance with the development of studies
about tumors of the heart and great vessels.
Epidemiology and incidence
The cardiovascular tumor is rarely encountered, and its
incidence is very low among tumors of all organs. In the
past, cardiac tumors are very difficult to diagnose before
life and it was often discovered incidentally at autopsy.
However, recent advances in diagnostic techniques such as
echocardiography and computed tomography (CT) enabled
clinical diagnosis during lifetime, and pathological diag-
nosis of tumor can be obtained by surgically removed
tumors or biopsy. From these accumulated pathological
and clinical data, it became evident that many varieties of
tumors occur in the heart and great vessels as in other
organs.
The incidence of cardiac tumors in autopsy
The incidence of cardiac tumors in autopsy cases has been
reported from long time ago, it has been observed differ-
ence almost 100 times by the reporter from 0.33 to
0.0017 % so far as in the literatures (Table 4). This wide
range of incidence may be due to changes of criteria for
pathological diagnosis, transition of subjects for autopsy,
and changes of diseases for autopsy [9, 10]. Pollia and
Gogol [11] reported the highest incidence of tumors orig-
inated from the heart as 0.33 % (154 cases) in autopsy of
46,072 cases, while Straus and Merliss [12] reported the
lowest incidence as 0.0017 % (8 cases) in autopsy of
480,000 cases by summarizing the autopsy statistics of six
hospitals. Reynen [13] reported the incidence as 0.021 %
in 731,309 autopsy cases by summarizing the autopsy
statistics from the 22 literatures. It is interesting the pres-
ence of year difference of incidence of tumors originated
from the heart that incidence of the years 1915–1931 is
0.047 %, while 0.17 % in the years 1954-1979 from the
report of Mayo Clinic [10, 14]. In Japan, Mukai et al. [15]
from National Cancer Center reported that tumors origi-
nated from the heart was found only in 1 case (0.038 %)
during the year 1976–1985 among 2,649 autopsy cases
who died of cancer. On the other hand, reports of cardiac
tumors in children are scarce, Nadas and Ellison [16]







Pollia 46,072 154 0.33
Benjamin 40,000 12 0.003
Straus 480,000 8 0.0017
Reynen 731,309 15,357 0.021
Mayo clinic
Lymburner: 1915–1931 8,550 4 0.047
Wold: 1954–1979 23,673 41 0.17
Mukai 2,649 1 0.038
Nadas 0.01
Modified from reference [10]
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reported that incidence of tumors originated from the heart
was 0.01 % at autopsy.
Tumors originated from the heart
The incidence of tumors originated from the heart has
changed over the years and the development of medicine
between the recent era when the diagnostic methods and
surgical resection developed and the era when most of the
cardiac tumors were diagnosed by autopsy.
In the AFIP data [3, 17], cardiac myxoma is the most
common cardiac tumor accounting for 24–37 % of them,
following angiosarcoma (7.3–8.5 %), and papillary fibro-
elastoma is observed (from 7.9–8.0 %) with approximately
the same frequency. Benign tumors are more common in
order of myxoma, papillary fibroelastoma, rhabdomyoma,
fibroma, hemangioma, and cystic tumor of atrioventricular
node, and malignant tumors are more common in order of
angiosarcoma, unclassified sarcoma, and malignant fibrous
histiocytoma (Table 5). In comparison with adults, the
Table 5 Incidence of tumors
originated from the heart
Modified from references [3,
17]
AFIP Armed Forces Institute of
Pathology
Tumors AFIP—1975 AFIP 1976–1993 Surgical cases
Benign
Myxoma 130 (24.4 %) 114 (29.5 %) 102 (36.7 %)
Papillary fibroelastoma 42 (7.9 %) 31 (8.0 %) 8 (2.9 %)
Rhabdomyoma 36 (6.8 %) 20 (5.2 %) 6 (2.2 %)
Fibroma 17 (3.2 %) 20 (5.2 %) 18 (6.5 %)
Hemangioma 15 (2.8 %) 17 (4.4 %) 10 (3.6 %)
Lipomatous hypertrophy 0 12 (3.1 %) 7 (2.5 %)
Cystic tumor of AV node 12 (2.3 %) 10 (2.6 %) 0
Granular cell tumor 3 (0.56 %) 4 (1.0 %) 0
Lipoma 45 (8.4 %) 2 (0.5 %) 2 (0.07 %)
Paraganglioma 0 2 (0.5 %) 2 (0.07 %)
Hamartoma 0 2 (0.5 %) 2 (0.07 %)
Histiocytoid cardiomyopathy 0 2 (0.5 %) 0
Inflammatory pseudotumor 0 2 (0.5 %) 2 (0.07 %)
Fibrous histiocytoma 0 1 (0.25 %) 0
Epithelioid hemangioendothelioma 0 1 (0.25 %) 1 (0.04 %)
Pericardial cyst 82 (15.4 %) 0 0
Bronchogenic cyst 7 (1.3 %) 1 (0.25 %) 1 (0.04 %)
Teratoma 14 (2.6 %) 1 (0.25 %) 0
Others 5 (0.94 %) 0 0
Total 408 (76.5 %) 242 (62.7 %) 161 (57.9 %)
Malignant
Angiosarcoma 39 (7.3 %) 33 (8.5 %) 22 (7.9 %)
Undifferentiated sarcoma 0 33 (8.5 %) 30 (10.8 %)
Malignant fibrous histiocytoma 0 16 (4.1 %) 16 (5.8 %)
Osteosarcoma 5 (0.94 %) 13 (3.4 %) 13 (4.7 %)
Leiomyosarcoma 1 (0.19 %) 12 (3.1 %) 11 (4.0 %)
Fibrosarcoma 14 (2.6 %) 9 (2.3 %) 9 (3.2 %)
Myxosarcoma 0 8 (2.1 %) 8 (2.9 %)
Rhabdomyosarcoma 26 (4.9 %) 6 (1.6 %) 2 (0.07 %)
Synovial sarcoma 1 (0.19 %) 4 (1.0 %) 4 (1.4 %)
Liposarcoma 1 (0.19 %) 2 (0.5 %) 0
Malignant schwannoma 4 (0.75 %) 1 (0.25 %) 1 (0.04 %)
Malignant mesothelioma 19 (3.6 %) 0 0
Others 8 (3.6 %) 0 0
Total 118 (23.5 %) 137 (35.5 %) 116 (41.7 %)
Malignant lymphoma 7 (1.3 %) 7 (1.8 %) 1 (0.04 %)
Total 533 386 278
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incidence of cardiac tumors in children is very low [3, 16].
In addition, percentages of rhabdomyoma and fibroma are
especially high, and histiocytoid cardiomyopathy also is
relatively high, but cardiac myxoma which is the most
common in adults is characterized as less common [3, 18]
(Table 6). Interestingly, rhabdomyoma is considered a
Table 6 Incidence of tumors
originated from the heart in
infancy (under 16 years)
Modified from references [3,
18]
AFIP Armed Forces Institute of
Pathology
Tumors AFIP \16 years Becker
\1 year \16 years
Benign
Myxoma 0 4 (7.1 %) 0
Rhabdomyoma 19 (54.3 %) 20 (35.7 %) 9 (42.9 %)
Fibroma 8 (22.9 %) 13 (23.2 %) 5 (23.8 %)
Histiocytoid cardiomyopathy 2 (5.7 %) 2 (3.6 %) 2 (9.5 %)
Hemangioma 1 (2.9 %) 2 (3.6 %) 2 (9.5 %)
Cystic tumor of AV node 1 (2.9 %) 2 (3.6 %) 0
Inflammatory pseudotumor 0 1 (1.8 %) 0
Teratoma 1 (2.9 %) 1 (1.8 %) 0
Lipoma 0 0 1 (4.8 %)
Total 32 (91.3 %) 45 (80.4 %) 19 (90.5 %)
Malignant
Rhabdomyosarcoma 1 (2.9 %) 3 (5.4 %) 0
Angiosarcoma 0 1 (1.8 %) 0
Undifferentiated sarcoma 1 (2.9 %) 3 (5.4 %) 1 (4.8 %)
Malignant fibrous histiocytoma 1 (1.8 %) 0
Leiomyosarcoma 1 (2.9 %) 1 (1.8 %) 1 (4.8 %)
Fibrosarcoma 0 1 (1.8 %) 0
Myxosarcoma 0 1 (1.8 %) 0
Total 3 (8.7 %) 11 (19.6 %) 2 (9.5 %)
Total 35 56 21













All sarcomas 41 years 67.2
Myxoma 50 years 58.5 64.0
Mesothelioma 57 years
Angiosarcoma 57.4
Papillary fibroelastoma 59 years 70.9
Lipomatous hypertrophy 64 years
Leiomyosarcoma 69.8
Modified from reference [9]
AFIP Armed Forces Institute of Pathology




Myxoma 125 (34.0 %) 100 (43.1 %)
Papillary fibroelastoma 42 (11.4 %) 41 (17.7 %)
Lipoma 9 (2.4 %) 8 (3.4 %)
Hemangioma 9 (2.4 %) 6 (2.6 %)
Fibroma 5 (1.4 %) 5 (2.2 %)
Lipomatous hypertrophy 3 (0.8 %) 2 (0.9 %)
Rhabdomyoma 1 (0.3 %) 0
Paraganglioma 1 (0.3 %) 2 (0.9 %)
Neurinoma 1 (0.3 %) 1 (0.45 %)
Hamartoma 1 (0.3 %) 0
Lipomatous hamartoma of cardiac
values
1 (0.3 %) 0
Inflammatory pseudotumor 0 1 (0.45 %)
Angiomyolipoma 0 1 (0.45 %)
Total 198 (53.8 %) 167 (72.0 %)
Malignant
Angiosarcoma 30 (8.2 %) 22 (9.5 %)
Malignant fibrous histiocytoma 12 (3.3 %) 10 (4.3 %)
Leiomyosarcoma 7 (1.9 %) 5 (2.2 %)
Liposarcoma 4 (1.1 %) 2 (0.9 %)
Osteosarcoma 3 (0.8 %) 3 (1.3 %)
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specific tumor which in some cases disappears in the
course of observation [16]. In children, malignant tumors
originated from the heart are very rare, and leiomyosar-
coma, unclassified sarcoma, and rhabdomyosarcoma are
reported [3, 16].
In this way, the susceptible age when cardiac tumors
have been diagnosed is different for each tumor. According
to the AFIP data [3], rhabdomyoma and teratoma occur in
infancy, rhabdomyosarcoma and cardiac fibroma is com-
mon in the adolescence, mesothelioma, lipomatous
hyperplasia, and papillary fibroelastoma tended to occur in
the elderly [3, 9, 19] (Table 7). Our results of research
about cardiac tumors in Japan supported by the Grant-in-
aid for Scientific Research from Japan Society for the
Promotion of Science (JSPS: 21591793) is not similar to
that of the data of AFIP for susceptible age when cardiac
tumors were diagnosed. This may be due to the small
number of cases in our study compared to AFIP data and
recent high incidences of presentation of cardiac tumors in
the elderly in recent aging society.
Cardiac tumors have been reported frequently in the
regional meetings of the Japanese Association for Thoracic
Surgery (JATS) and the Japanese Circulation Society (JCS).
Compiling the tumor incidence by reported cases that have
been reported in the meeting of regional meeting of JATS
and JCS during the years 1999–2010, the most frequent
benign tumor was cardiac myxoma (34.0–43.1 %), fol-
lowed by papillary fibroelastoma (11.4–17.7 %), lipoma
(2.4–3.4 %), and hemangioma (2.4–2.6 %) in the order [9]
(Table 8). On the other hand, frequency of the malignant
cardiac tumor with the exception of malignant lymphoma
was angiosarcoma (8.2–9.5 %), malignant fibrous histio-
cytoma (3.3–4.3 %), and leiomyosarcoma (1.9–2.2 %) in
the order. Although the approximate frequency rate of
cardiac tumors were similar among regional meeting of
JATS and JCS, it may be possible that the same case have
been reported in both meetings. However, for malignant
lymphoma, different incidence between JCS: 20.4 % and




















Fig. 1 Changes of cases of reported cardiac tumors by the annual report by The Japanese Association for Thoracic Surgery
Table 8 continued
Tumors JCS JATS
Synovial sarcoma 3 (0.8 %) 2 (0.9 %)
Rhabdomyosarcoma 3 (0.8 %) 1 (0.45 %)
Fibrosarcoma 2 (0.3 %) 0
Chondrosarcoma 0 1 (0.45 %)
Malignant schwannoma 0 1 (0.45 %)
Endothelial sarcoma 0 2 (0.9 %)
Epithelioid hemangioendothelioma 0 1 (0.45 %)
Others 31 (8.4 %) 1 (0.45 %)
Total 95 (25.8 %) 51 (22.0 %)
Malignant lymphoma 75 (20.4 %) 14 (6.0 %)
Total 368 232
Modified from reference [9]
JCS Japanese Circulation Society, JATS Japanese Association for
Thoracic Surgery
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chemotherapy is the subject of treatment and surgery have
been attempted to patients only for open biopsy due to
failure of non-invasive tissue diagnosis or for life-saving
surgery for patients suffering from heart failure due to
intracavitary obstructing tumor. In addition, since the rela-
tively rare cases tend to be reported at such regional
meetings, it is plausible that these data did not reflect the
actual incidence of tumor in Japan.
Regarding number of cases of surgery for cardiac
tumors in Japan, there are annual statistics of JATS; since
the survey began in 1986, incidence of cardiac tumor has
been increasing every year. Recently, about 400–500 cases
have been operated in every year, and cardiac myxoma
accounts for about 70 % of them (Fig. 1).
By our research project for cardiac tumors in Japan
supported by the Grant-in-aid for scientific research from
Japan Society for the Promotion of Science, we send out
questionnaires to the JATS- and JCS-certified 1,789 hos-
pitals in 2010 asking the cardiac tumor incidence between
January and December, 2009. As a result, 580 cases with
cardiovascular tumors have been experienced in 326 hos-
pitals, most of 389 cases (67.1 %) were benign tumors
originated from the heart, following malignant tumors
originated from the heart were 90 cases (15.5 %) and
metastatic tumors were 75 cases (12.9 %) [9] (Table 9). In
addition, 12 cases of pericardial tumor (2.1 %), and 14
cases of tumor of the great vessels (2.4 %) have been
experienced. Considering the annual statistics from JATS
and this clinical epidemiological study in Japan, it is
Table 9 Incidence of tumors originated from the heart and the
pericardium in Japan (2009)
Tumors Cases
Benign
Myxoma 332 (69.9 %)
Papillary fibroelastoma 46 (9.7 %)
Rhabdomyoma 5 (1.1 %)
Lipomatous hypertrophy 1 (0.2 %)
Lipoma 1 (0.2 %)
Granular cell tumor 1 (0.2 %)
Paraganglioma 1 (0.2 %)
Neurinoma 1 (0.2 %)
Hamartoma 1 (0.2 %)
PEComa 1 (0.2 %)
Total 390 (82.1 %)
Malignant
Angiosarcoma 14 (3.0 %)
Malignant fibrous histiocytoma 5 (1.1 %)
Rhabdomyosarcoma 4 (0.8 %)
Leiomyosarcoma 4 (0.8 %)
Osteosarcoma 2 (0.4 %)
Synovial sarcoma 1 (0.2 %)
Total 30 (6.3 %)
Malignant lymphoma 43 (9.1 %)
Unknown 10 (2.1 %)
Pericardial tumor
Malignant mesothelioma 2 (0.4 %)
Total 475
Modified from reference [9]
PEComa perivascular epithelioid cell tumor
Table 10 Reported incidences
of metastatic cardiac tumors
Modified from reference [20]
Authors Years Autopsy cases Cancer cases Cardiac metastasis Incidence (%)
In cancer cases In autopsy cases
1917–1951
Symmers 1917 298 5 1.7
Willis 1933 323 20 6.2
Burke 1934 327 14 4.3
Pollia 1936 1,450 29 2.0
Scott 1939 1,082 101 9.3
Ritchie 1941 857 16 1.9
Prichard 1951 4,375 146 3.3
Total 8,712 331 3.8
1975–2007
Abioye 1975 6,064 752 64 8.5 1.1
Ambrosio 1980 2,222 590 38 6.4 1.7
Xiong 1986 2,050 484 68 14.0 3.3
Karwinski 1989 8,571 2,833 130 4.6 1.5
MacGee 1991 2,455 1,311 57 4.4 2.4
Silvestri 1997 4,769 1,928 162 8.4 3.4
Abraham 1999 3,314 806 95 11.8 2.9
Rafajlovski 2005 11,403 2,928 79 2.7 0.7
Bussani 2007 18,751 7,289 662 9.1 3.5
Total 59,599 18,921 1,355 7.1 2.3
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estimated that the tumors originated from the heart occurs
near 500 cases per year. In this study, tumors originated
from the heart have been reported 489 cases. Among these
cases, the 390 cases (79.8 %) of benign cardiac tumors were
more than malignancy, and 332 cases (67.8 %) were cardiac
myxoma, followed by 46 cases of papillary fibroelastoma
(9.4 %), 5 cases of rhabdomyoma (1.0 %), lipomatous
hyperplasia, lipoma, granular cell tumor, paraganglioma,
schwannoma, hamartoma, and perivascular epithelioid cell
tumor. Eighty-eight cases (18.0 %) were malignant tumors
originated from the heart, among them 43 cases (8.9 %)
were malignant lymphoma, followed 9 cases (3.5 %) of
Table 11 Metastatic cardiac and pericardial tumors
Primary lesions Mukai Butany
Heart pericardium Total (%) (%)
Lung 104 32 136 (33.4) 89 (33.7)
Breast 27 8 35 (8.6) 31 (11.7)
Stomach 22 8 30 (7.4) 3 (1.1)
Malignant lymphoma 25 2 27 (6.6) 24 (9.1)
Esophagus 18 7 25 (6.1) 8 (3.0)
Leukemia/Myeloma 20 2 22 (5.4) 32 (12.1)
Uterus 18 2 20 (4.9)
Malignant melanoma 19 19 (4.7) 8 (3.0)
Sarcoma 14 3 17 (4.2)
Rectum 9 3 12 (2.9) 9 (3.4)
Tongue 9 2 11 (2.7)
Germ cell tumor 8 1 9 (2.2)
Thyroid 6 6 (1.5) 1 (0.4)
Kidney 4 1 5 (1.2) 3 (1.1)
Oral cavity 4 4 (1.0) 3 (1.1)
Salivary gland 3 1 4 (1.0)
Larynx 1 2 3 (1.0) 1 (0.4)
Pharynx 1 2 3 (1.0)
Thymus 3 3 (1.0)
Skin 2 2 (0.5)
Bile duct 2 2 (0.5)
Pancreas 2 2 (0.5) 10 (3.8)
Urinary bladder 2 2 (0.5)
Unknown 2 2 (0.5) 16 (6.1)
Neuroblastoma 1 1 (0.5)
Nasal/paranasal sinus 1 1 (0.25)
Small intestine 1 (0.4)
Liver 1 1 (0.25) 2 (0.8)
Prostate 1 1 (0.25)
Ovarium 1 1 (0.25)
External genitalia 1 1 (0.25)
Malignant melanoma 5 (1.9)
Reproductive organ 6 (2.3)
Soft tissue 8 (3.0)
Mediastinum 2 (0.8)
Brain 2 (0.8)
Total 324 83 407 264
Modified from reference [9]




Direct invasion 32 (27.6 %)
Mediastinal tumors 11 (9.5 %)
Thymic cancer 8 (6.9 %)
Germ cell tumor 1
Malignant lymphoma 1
Unknown 1
Lung cancer 19 (16.4 %)
Esophageal cancer 2 (1.7 %)
Distant metastasis 39 (34.5 %)
Thyroid cancer 5 (4.3 %)
Breast cancer 3 (2.6 %)
Lung cancer 4 (3.4 %)
Gastrointestinal cancer 12 (10.3 %)
Esophageal cancer 2 (1.7 %)
Gastric cancer 3 (2.6 %)
Colon cancer 1
Hepatoma 3 (2.6 %)
Unknown 3 (2.6 %)
Kidney cancer 4 (3.4 %)
Seminoma 1
Germ cell tumor 1
Urinary bladder cancer 1
Uterus cancer 1
Osteosarcoma 1
Soft tissue tumor 1
Unknown 5 (4.3 %)
Intravascular extension 33 (28.4 %)
Renal cancer 24 (20.7 %)
Uterine tumor 3 (2.6 %)
Colon cancer 3 (2.6 %)
Hepatoma 2 (1.7 %)
Thyroid cancer 1
Ureteral cancer 1
Pericardium 12 (10.3 %)
Malignant thymoma 3 (2.6 %)
Leukemia 3 (2.6 %)






Modified from references [9]
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angiosarcoma, 17 cases (1.8 %) of rhabdomyosarcoma, 5
cases (1.0 %) of malignant fibrous histiocytoma, and 2
cases (0.4 %) of osteosarcoma. As of pericardial tumor, two
cases of malignant mesothelioma were reported. Tumors of
the great vessels were extremely rare. Pulmonary artery
tumors were most frequent, among them intimal sarcoma in
five cases, angiosarcoma in two cases, and one case of
leiomyosarcoma. Two cases of metastatic aortic tumors
(thymic carcinoma, esophageal carcinoma) were reported,
and in the vena cava tumors, one case of primary angio-
sarcoma and three metastatic tumors were reported.
Metastatic cardiac tumors
Pathway of metastasis from other organs to the heart or
pericardium are direct invasion from nearby organs such as
lung, mediastinum or esophagus, distant metastasis by
lymphatic metastasis or hematogenous metastasis, exten-
sion of the tumor via vena cava or pulmonary vein to the
heart chamber, or combination of these routes.
The incidence of metastatic cardiac tumors in autopsy
cases has been reported 0.7–3.5 % and in autopsy cases of
malignant tumor has been reported 1.7–14 %; thus meta-
static cardiac tumors are more frequent than malignant
tumors originated from the heart [20] (Table 10). Lym-
burner [14] reported high incidence of metastatic cardiac
tumors as 52 cases (0.61 %) and malignant tumors origi-
nated from the heart as 4 cases (0.047 %) in 8,550 autopsy
cases, which ratio is 13:1 in 1934.
Mukai et al. [15] reported that during a 10-year period
(1976–1985), only one case of a primary malignant meso-
thelioma (0.038 %) was identified among 2,649 autopsies
Table 13 Frequency of metastasis to the heart and the pericardium in autopsy cases
AFIP Mukai
Tumors Autopsy heart Pericardium Total (%) Autopsy Heart Pericardium Total (%)
Malignant melanoma 69 32 2 34 (49) 28 19 0 19 (67.5)
Germ cell tumor 21 8 1 9 (43) 21 8 1 9 (42.9)
Leukemia 202 66 2 68 (34) 103 20 2 22 (21.4)
Lung cancer 1,037 180 112 292 (28) 484 04 32 136 (28.1)
Sarcoma 159 24 11 35 (22) 90 14 3 17 (18.9)
Malignant lymphoma 392 67 15 82 (21) 147 25 2 27 (18.4)
Breast cancer 685 70 69 139 (20) 193 27 8 35 (18.1)
Esophageal cancer 294 37 13 50 (17) 187 18 7 25 (13.4)
Renal cancer 114 12 5 17 (15) 61 4 1 5 (8.2)
Oral cavity/tongue cancer 235 22 2 24 (10) 104 16 3 19 (18.3)
Laryngeal cancer 100 9 2 11 (11) 67 1 2 3 (4.5)
Thyroid cancer 97 9 3 12 (12) 77 6 0 6 (7.8)
Uterine cancer 451 36 5 41 (9) 195 18 2 20 (10.3)
Gastric cancer 603 28 16 44 (7) 391 22 8 30 (7.7)
Colon cancer 440 22 3 25 (6) 167 9 3 12 (7.2)
Pharyngeal cancer 67 1 2 3 (4.5) 34 1 2 3 (8.8)
Urinary bladder cancer 128 8 0 8 (6) 47 2 0 2 (4.3)
Ovarian cancer 188 2 6 8 (4) 49 1 0 1 (2.0)
Prostate cancer 171 6 0 6 (4) 48 1 0 1 (2.0)
Nasal/paranasal sinus cancer 32 1 0 1 (3) 32 1 0 1 (3.1)
Pancreatic cancer 185 6 0 6 (3) 89 2 0 2 (2.2)
Hepato-biliary cancer 325 7 0 7 (2) 250 3 2 5 (2.0)
Malignant thymoma 5 3 0 3 (60.0)
Skin cancer 14 2 0 2 (14.3)
External genital cancer 7 0 1 1 (14.3)
Neuroblastoma 11 0 1 1 (9.1)
Unknown 9 2 0 2 (22.2)
Others 82 0 0 0
Total 6,240 654 299 953 (15) 2,992 324 83 407 (13.6)
Modified from reference [9]
AFIP Armed Forces Institute of Pathology
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of malignant tumors at the National Cancer Center Hospital,
in contrast, there were 407 cases (15.4 %) in which heart
and/or pericardium were secondarily involved with a
malignant tumor from other organs. Burke indicated that if
one accepts a rate of 1 to 3 % for cardiac metastases occur
in autopsy, and a rate of 1 to 3 % for malignant tumors
originated from the heart seen in autopsy, then the ratio of
cardiac metastases to malignant tumors originated from the
heart is 100:1 to 1,000:1. They suggested that this estimate
is so higher than previous estimate 1:20 to 1:40; thus, a ratio
that falls within the range of 100 to 1,000:1 is likely an
accurate estimate of the true ratio of metastatic tumors to
malignant tumors originated from the heart [3]. Since
Butany et al. [21] reported that two malignant tumors
originated from the heart (0.017 %) and 264 metastatic
tumors (2.31 %) were identified among 11,432 autopsies
(the ratio of malignant tumors originated from the heart to
metastatic tumors 1:132), Burke’s estimate is plausible.
Lung cancer is the most high incident metastatic cardiac
tumor followed by breast cancer, malignant melanoma,
leukemia, and malignant lymphoma [15, 21] (Table 11). In
our study about cardiac tumors in Japan supported by the
Grant-in-aid for scientific research revealed that among
116 metastatic tumors, direct invasion to the heart was 32
cases (27.6 %), distant metastasis from other organ cancer
was 39 cases (34.5 %), and intravenous extension of the
tumor was 33 cases (28.4 %) (Table 12). As the rate of
metastases to the heart and pericardium (number of cases
with metastases to the heart/number of autopsy of malig-
nancy for each 9100), malignant melanoma most fre-
quently metastasizes to the heart (49–67.5 %), followed by
germ cell tumors (43 %), leukemia (21.4–34 %), malignant
lymphoma (18.4–21 %), and others [3, 15] (Table 13).
Bussani et al. [22] reported the study for an autopsy of
18,751 cases, and among 7,289 cases of malignant tumor
metastasis to the heart was found in 622 cases (9.1 %).
Malignant pleural mesothelioma showed the highest rate
(48.4 %) of metastasis, followed by malignant melanoma
(27.8 %) and lung adenocarcinoma (21 %). In addition, the
frequency rate of lung cancer was different in accordance
with the pathology of the lung cancer, and in adenocarci-
noma it was 21 %, undifferentiated carcinoma 19.5 %,
squamous cell carcinoma 18.2 %, and bronchoalveolar
carcinoma 9.8 %.
The metastatic site of the metastatic tumor in the heart
are to the heart, pericardium, and both heart and pericar-
dium. Mukai et al. [15] reported that among 407 cases of
cardiac metastasis, metastasis to the myocardium was 169
cases (41.5 %), followed by epicardium 136 cases
(33.4 %), pericardium 78 cases (19.2 %), and endocardium
24 cases (5.9 %), and Butany et al. [21] reported that
among 193 cases of cardiac metastasis, metastasis to the
pericardium was 127 cases (65.8 %), myocardium 56 cases
(29.0 %), epicardium 48 cases (24.9 %), and endocardium
6 cases (3.1 %) [12, 21] (Table 14). The differences of the
incidence of metastatic cardiac tumor by reporters may be
due to what kind of hospital, i.e., general hospital, cancer
specialized hospital or cardiovascular specialized hospital,
or whether hospital has system to perform an autopsy and
department pathology or not [21]. It is also possible that the
statistical results are different depending on whether to
include the hematopoietic tumors such as leukemia and
malignant lymphoma. While there is a report that incidence
of metastatic cardiac tumor does not significantly change
with time [23], Mukai et al. [15] reported increase in its
incidence from 9.7 % in 1996 report to 15.4 % in 1988. In
addition, according to the study of the reported cases
summarized by Al-Mamgani et al. [20], its incidence prior
to 1975 was 3.8 % and subsequent significant increased to
7.1 % in recent years.
Formerly, most of the metastatic cardiac tumors have
been so far reported in autopsy cases. Recent advances of
diagnostic imaging methods by CT, MRI, and echocardi-
ography enabled to discover metastasis to the heart early
even in the absence of symptoms related to the heart, such
as arrhythmia and heart failure [24]. In addition to these
development of diagnostic tools, incidence of metastatic
cardiac tumors may increase further by life-prolonging
effect by anti-cancer drugs .
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Table 14 Metastatic sites of the heart and the pericardium
Sites Mukai Butany
Heart/pericardium 407





Pericardium 78 (19.2 %) 127 (65.8 %)
Epicardium 136 (33.4 %) 48 (24.9 %)
Myocardium 169 (41.5 %) 56 (29.0 %)
Endocardium 4 (5.9 %) 6 (3.1 %)
Localization of involvement
Right side only 34
Left side only 50
Septum only 10
Bilateral or diffuse 52
Intracavitary tumor thrombus 7
Modified from reference [9]
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